In early 2015, ZappRx announced Series A funding, including a $5.6 million round led by SR One, the venture arm of GlaxoSmithKline, with participation from Atlas Venture. Since then, the company has grown to 20 employees, raised $14M, and anticipates additional growth.
"I have seen firsthand how the biopharmaceutical industry is in great need of ZappRx's solutions," said DiCesare. "I am joining the company at a critical time, when the number of specialty therapies available and their costs have increased. Yet, despite market growth, drug manufacturers often don't have real-time information to evaluate performance and improve access for patients."
U.S. spending on prescription drugs is projected to reach $500B by 2020. Specialty drugs represent less than 2% of prescriptions written, but account for almost 40% of drug spending. The process of getting a drug from prescription to patient is cumbersome and delays patient access to critical therapy.
ZappRx is modernizing and simplifying the way specialty medications are managed. The company provides a secure, collaborative online platform that allows patients, physicians, and pharmacists to work together to improve patients' access to treatment, delivering medicine faster, with fewer hassles and greater transparency. ZappRx is on the web at ZappRx.com. Follow ZappRx on Twitter at twitter.com/zapprx.
Heath Umbach, Sr. Director of Marketing and Business Development
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zapprx-hires-biopharmaceutical-industry-leader-as-chief-operating-officer-300330572.html